Rheumatology:使用可穿戴设备评估风湿性疾病的体力活动,一项系统回顾和荟萃分析

2022-08-31 紫菀款冬 MedSci原创

在风湿性肌肉骨骼疾病的治疗中,规律的体力活动是一种重要的非药物干预。该系统综述和荟萃分析旨在评估可穿戴设备的使用如何影响非炎症性和炎性风湿性疾病患者的体力活动。

目的:在风湿性肌肉骨骼疾病(RMDs)的治疗中,规律的体力活动(PA)是一种重要的非药物干预。该系统综述和荟萃分析旨在评估可穿戴设备(WDs)的使用如何影响非炎症性和炎性风湿性疾病患者的体力活动。

方法:对PubMed、Embase、CINAHL和Scopus的文章进行全面搜索。对步数中等强度体力活动(MVPA)进行随机效应荟萃分析。计算单变量荟萃回归模型,以评估研究特征可能作为最终荟萃分析估计的修正因素的可能性。

结果:在分析中,纳入了51篇文章,共有7488名参与者。22项研究仅考虑了MVPA结果,16项研究单独考虑了步数,13项研究报告了两种结果的信息。

MVPA达到了推荐的PA阈值(36.35,95%CI  29.39-43.31),但日常步数未达到(-1092.60,-1640.42-544.77)。

对纤维肌痛患者的研究报告显示,与其他RMD相比,纤维肌痛患者每日步数更高(6290,5198.65-7381.62)。

受慢性炎性关节病影响的患者在日常活动方面似乎比其他类别的患者表现更好。在步数和MVPA方面,年龄较小的患者报告的PA总体水平高于老年人

结论:当使用WD客观测量时,RMDs患者的体力活动可能低于推荐阈值。WDs可能是RMD中日常监测身体活动的有用且负担得起的工具,并可能支持活动水平的提高

 

文献来源:

Ocagli H, Agarinis R, Azzolina D, et al. Physical activity assessment with wearable devices in rheumatic diseases: a systematic review and meta-analysis [published online ahead of print, 2022 Aug 25]. Rheumatology (Oxford). 2022;keac476. doi:10.1093/rheumatology/keac476

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1681482, encodeId=ff04168148241, content=<a href='/topic/show?id=366b8e2299e' target=_blank style='color:#2F92EE;'>#荟萃#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87229, encryptionId=366b8e2299e, topicName=荟萃)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c12d27855367, createdName=venlin, createdTime=Tue Dec 13 23:50:46 CST 2022, time=2022-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2062616, encodeId=240e206261628, content=<a href='/topic/show?id=872c15438a4' target=_blank style='color:#2F92EE;'>#Rheumatology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15438, encryptionId=872c15438a4, topicName=Rheumatology)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3307462, createdName=风铃821, createdTime=Tue May 30 22:50:46 CST 2023, time=2023-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1837035, encodeId=4a54183e035b7, content=<a href='/topic/show?id=1f188e230c5' target=_blank style='color:#2F92EE;'>#荟萃分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=171, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87230, encryptionId=1f188e230c5, topicName=荟萃分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b79433, createdName=fangcong, createdTime=Sun Jan 15 02:50:46 CST 2023, time=2023-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1953955, encodeId=6df91953955e5, content=<a href='/topic/show?id=88ece544685' target=_blank style='color:#2F92EE;'>#穿戴设备#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75446, encryptionId=88ece544685, topicName=穿戴设备)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7dc7399, createdName=apoenzyme, createdTime=Wed Jun 14 23:50:46 CST 2023, time=2023-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1700699, encodeId=42db1e006992a, content=<a href='/topic/show?id=82bc38512a4' target=_blank style='color:#2F92EE;'>#可穿戴设备#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38512, encryptionId=82bc38512a4, topicName=可穿戴设备)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db8830213477, createdName=shalley76, createdTime=Fri Mar 31 01:50:46 CST 2023, time=2023-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1361352, encodeId=90521361352cb, content=<a href='/topic/show?id=15ac10083129' target=_blank style='color:#2F92EE;'>#风湿性疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100831, encryptionId=15ac10083129, topicName=风湿性疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Tue Aug 30 15:50:46 CST 2022, time=2022-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1576444, encodeId=135515e644459, content=<a href='/topic/show?id=e02ee6901a2' target=_blank style='color:#2F92EE;'>#系统回顾#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76901, encryptionId=e02ee6901a2, topicName=系统回顾)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=27e316318097, createdName=ms5822920152752585, createdTime=Tue Aug 30 15:50:46 CST 2022, time=2022-08-30, status=1, ipAttribution=)]
    2022-12-13 venlin
  2. [GetPortalCommentsPageByObjectIdResponse(id=1681482, encodeId=ff04168148241, content=<a href='/topic/show?id=366b8e2299e' target=_blank style='color:#2F92EE;'>#荟萃#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87229, encryptionId=366b8e2299e, topicName=荟萃)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c12d27855367, createdName=venlin, createdTime=Tue Dec 13 23:50:46 CST 2022, time=2022-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2062616, encodeId=240e206261628, content=<a href='/topic/show?id=872c15438a4' target=_blank style='color:#2F92EE;'>#Rheumatology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15438, encryptionId=872c15438a4, topicName=Rheumatology)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3307462, createdName=风铃821, createdTime=Tue May 30 22:50:46 CST 2023, time=2023-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1837035, encodeId=4a54183e035b7, content=<a href='/topic/show?id=1f188e230c5' target=_blank style='color:#2F92EE;'>#荟萃分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=171, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87230, encryptionId=1f188e230c5, topicName=荟萃分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b79433, createdName=fangcong, createdTime=Sun Jan 15 02:50:46 CST 2023, time=2023-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1953955, encodeId=6df91953955e5, content=<a href='/topic/show?id=88ece544685' target=_blank style='color:#2F92EE;'>#穿戴设备#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75446, encryptionId=88ece544685, topicName=穿戴设备)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7dc7399, createdName=apoenzyme, createdTime=Wed Jun 14 23:50:46 CST 2023, time=2023-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1700699, encodeId=42db1e006992a, content=<a href='/topic/show?id=82bc38512a4' target=_blank style='color:#2F92EE;'>#可穿戴设备#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38512, encryptionId=82bc38512a4, topicName=可穿戴设备)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db8830213477, createdName=shalley76, createdTime=Fri Mar 31 01:50:46 CST 2023, time=2023-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1361352, encodeId=90521361352cb, content=<a href='/topic/show?id=15ac10083129' target=_blank style='color:#2F92EE;'>#风湿性疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100831, encryptionId=15ac10083129, topicName=风湿性疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Tue Aug 30 15:50:46 CST 2022, time=2022-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1576444, encodeId=135515e644459, content=<a href='/topic/show?id=e02ee6901a2' target=_blank style='color:#2F92EE;'>#系统回顾#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76901, encryptionId=e02ee6901a2, topicName=系统回顾)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=27e316318097, createdName=ms5822920152752585, createdTime=Tue Aug 30 15:50:46 CST 2022, time=2022-08-30, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1681482, encodeId=ff04168148241, content=<a href='/topic/show?id=366b8e2299e' target=_blank style='color:#2F92EE;'>#荟萃#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87229, encryptionId=366b8e2299e, topicName=荟萃)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c12d27855367, createdName=venlin, createdTime=Tue Dec 13 23:50:46 CST 2022, time=2022-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2062616, encodeId=240e206261628, content=<a href='/topic/show?id=872c15438a4' target=_blank style='color:#2F92EE;'>#Rheumatology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15438, encryptionId=872c15438a4, topicName=Rheumatology)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3307462, createdName=风铃821, createdTime=Tue May 30 22:50:46 CST 2023, time=2023-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1837035, encodeId=4a54183e035b7, content=<a href='/topic/show?id=1f188e230c5' target=_blank style='color:#2F92EE;'>#荟萃分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=171, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87230, encryptionId=1f188e230c5, topicName=荟萃分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b79433, createdName=fangcong, createdTime=Sun Jan 15 02:50:46 CST 2023, time=2023-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1953955, encodeId=6df91953955e5, content=<a href='/topic/show?id=88ece544685' target=_blank style='color:#2F92EE;'>#穿戴设备#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75446, encryptionId=88ece544685, topicName=穿戴设备)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7dc7399, createdName=apoenzyme, createdTime=Wed Jun 14 23:50:46 CST 2023, time=2023-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1700699, encodeId=42db1e006992a, content=<a href='/topic/show?id=82bc38512a4' target=_blank style='color:#2F92EE;'>#可穿戴设备#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38512, encryptionId=82bc38512a4, topicName=可穿戴设备)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db8830213477, createdName=shalley76, createdTime=Fri Mar 31 01:50:46 CST 2023, time=2023-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1361352, encodeId=90521361352cb, content=<a href='/topic/show?id=15ac10083129' target=_blank style='color:#2F92EE;'>#风湿性疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100831, encryptionId=15ac10083129, topicName=风湿性疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Tue Aug 30 15:50:46 CST 2022, time=2022-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1576444, encodeId=135515e644459, content=<a href='/topic/show?id=e02ee6901a2' target=_blank style='color:#2F92EE;'>#系统回顾#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76901, encryptionId=e02ee6901a2, topicName=系统回顾)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=27e316318097, createdName=ms5822920152752585, createdTime=Tue Aug 30 15:50:46 CST 2022, time=2022-08-30, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1681482, encodeId=ff04168148241, content=<a href='/topic/show?id=366b8e2299e' target=_blank style='color:#2F92EE;'>#荟萃#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87229, encryptionId=366b8e2299e, topicName=荟萃)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c12d27855367, createdName=venlin, createdTime=Tue Dec 13 23:50:46 CST 2022, time=2022-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2062616, encodeId=240e206261628, content=<a href='/topic/show?id=872c15438a4' target=_blank style='color:#2F92EE;'>#Rheumatology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15438, encryptionId=872c15438a4, topicName=Rheumatology)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3307462, createdName=风铃821, createdTime=Tue May 30 22:50:46 CST 2023, time=2023-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1837035, encodeId=4a54183e035b7, content=<a href='/topic/show?id=1f188e230c5' target=_blank style='color:#2F92EE;'>#荟萃分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=171, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87230, encryptionId=1f188e230c5, topicName=荟萃分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b79433, createdName=fangcong, createdTime=Sun Jan 15 02:50:46 CST 2023, time=2023-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1953955, encodeId=6df91953955e5, content=<a href='/topic/show?id=88ece544685' target=_blank style='color:#2F92EE;'>#穿戴设备#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75446, encryptionId=88ece544685, topicName=穿戴设备)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7dc7399, createdName=apoenzyme, createdTime=Wed Jun 14 23:50:46 CST 2023, time=2023-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1700699, encodeId=42db1e006992a, content=<a href='/topic/show?id=82bc38512a4' target=_blank style='color:#2F92EE;'>#可穿戴设备#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38512, encryptionId=82bc38512a4, topicName=可穿戴设备)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db8830213477, createdName=shalley76, createdTime=Fri Mar 31 01:50:46 CST 2023, time=2023-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1361352, encodeId=90521361352cb, content=<a href='/topic/show?id=15ac10083129' target=_blank style='color:#2F92EE;'>#风湿性疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100831, encryptionId=15ac10083129, topicName=风湿性疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Tue Aug 30 15:50:46 CST 2022, time=2022-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1576444, encodeId=135515e644459, content=<a href='/topic/show?id=e02ee6901a2' target=_blank style='color:#2F92EE;'>#系统回顾#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76901, encryptionId=e02ee6901a2, topicName=系统回顾)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=27e316318097, createdName=ms5822920152752585, createdTime=Tue Aug 30 15:50:46 CST 2022, time=2022-08-30, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1681482, encodeId=ff04168148241, content=<a href='/topic/show?id=366b8e2299e' target=_blank style='color:#2F92EE;'>#荟萃#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87229, encryptionId=366b8e2299e, topicName=荟萃)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c12d27855367, createdName=venlin, createdTime=Tue Dec 13 23:50:46 CST 2022, time=2022-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2062616, encodeId=240e206261628, content=<a href='/topic/show?id=872c15438a4' target=_blank style='color:#2F92EE;'>#Rheumatology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15438, encryptionId=872c15438a4, topicName=Rheumatology)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3307462, createdName=风铃821, createdTime=Tue May 30 22:50:46 CST 2023, time=2023-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1837035, encodeId=4a54183e035b7, content=<a href='/topic/show?id=1f188e230c5' target=_blank style='color:#2F92EE;'>#荟萃分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=171, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87230, encryptionId=1f188e230c5, topicName=荟萃分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b79433, createdName=fangcong, createdTime=Sun Jan 15 02:50:46 CST 2023, time=2023-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1953955, encodeId=6df91953955e5, content=<a href='/topic/show?id=88ece544685' target=_blank style='color:#2F92EE;'>#穿戴设备#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75446, encryptionId=88ece544685, topicName=穿戴设备)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7dc7399, createdName=apoenzyme, createdTime=Wed Jun 14 23:50:46 CST 2023, time=2023-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1700699, encodeId=42db1e006992a, content=<a href='/topic/show?id=82bc38512a4' target=_blank style='color:#2F92EE;'>#可穿戴设备#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38512, encryptionId=82bc38512a4, topicName=可穿戴设备)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db8830213477, createdName=shalley76, createdTime=Fri Mar 31 01:50:46 CST 2023, time=2023-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1361352, encodeId=90521361352cb, content=<a href='/topic/show?id=15ac10083129' target=_blank style='color:#2F92EE;'>#风湿性疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100831, encryptionId=15ac10083129, topicName=风湿性疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Tue Aug 30 15:50:46 CST 2022, time=2022-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1576444, encodeId=135515e644459, content=<a href='/topic/show?id=e02ee6901a2' target=_blank style='color:#2F92EE;'>#系统回顾#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76901, encryptionId=e02ee6901a2, topicName=系统回顾)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=27e316318097, createdName=ms5822920152752585, createdTime=Tue Aug 30 15:50:46 CST 2022, time=2022-08-30, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1681482, encodeId=ff04168148241, content=<a href='/topic/show?id=366b8e2299e' target=_blank style='color:#2F92EE;'>#荟萃#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87229, encryptionId=366b8e2299e, topicName=荟萃)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c12d27855367, createdName=venlin, createdTime=Tue Dec 13 23:50:46 CST 2022, time=2022-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2062616, encodeId=240e206261628, content=<a href='/topic/show?id=872c15438a4' target=_blank style='color:#2F92EE;'>#Rheumatology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15438, encryptionId=872c15438a4, topicName=Rheumatology)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3307462, createdName=风铃821, createdTime=Tue May 30 22:50:46 CST 2023, time=2023-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1837035, encodeId=4a54183e035b7, content=<a href='/topic/show?id=1f188e230c5' target=_blank style='color:#2F92EE;'>#荟萃分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=171, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87230, encryptionId=1f188e230c5, topicName=荟萃分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b79433, createdName=fangcong, createdTime=Sun Jan 15 02:50:46 CST 2023, time=2023-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1953955, encodeId=6df91953955e5, content=<a href='/topic/show?id=88ece544685' target=_blank style='color:#2F92EE;'>#穿戴设备#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75446, encryptionId=88ece544685, topicName=穿戴设备)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7dc7399, createdName=apoenzyme, createdTime=Wed Jun 14 23:50:46 CST 2023, time=2023-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1700699, encodeId=42db1e006992a, content=<a href='/topic/show?id=82bc38512a4' target=_blank style='color:#2F92EE;'>#可穿戴设备#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38512, encryptionId=82bc38512a4, topicName=可穿戴设备)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db8830213477, createdName=shalley76, createdTime=Fri Mar 31 01:50:46 CST 2023, time=2023-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1361352, encodeId=90521361352cb, content=<a href='/topic/show?id=15ac10083129' target=_blank style='color:#2F92EE;'>#风湿性疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100831, encryptionId=15ac10083129, topicName=风湿性疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Tue Aug 30 15:50:46 CST 2022, time=2022-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1576444, encodeId=135515e644459, content=<a href='/topic/show?id=e02ee6901a2' target=_blank style='color:#2F92EE;'>#系统回顾#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76901, encryptionId=e02ee6901a2, topicName=系统回顾)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=27e316318097, createdName=ms5822920152752585, createdTime=Tue Aug 30 15:50:46 CST 2022, time=2022-08-30, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1681482, encodeId=ff04168148241, content=<a href='/topic/show?id=366b8e2299e' target=_blank style='color:#2F92EE;'>#荟萃#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87229, encryptionId=366b8e2299e, topicName=荟萃)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c12d27855367, createdName=venlin, createdTime=Tue Dec 13 23:50:46 CST 2022, time=2022-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2062616, encodeId=240e206261628, content=<a href='/topic/show?id=872c15438a4' target=_blank style='color:#2F92EE;'>#Rheumatology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15438, encryptionId=872c15438a4, topicName=Rheumatology)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3307462, createdName=风铃821, createdTime=Tue May 30 22:50:46 CST 2023, time=2023-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1837035, encodeId=4a54183e035b7, content=<a href='/topic/show?id=1f188e230c5' target=_blank style='color:#2F92EE;'>#荟萃分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=171, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87230, encryptionId=1f188e230c5, topicName=荟萃分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b79433, createdName=fangcong, createdTime=Sun Jan 15 02:50:46 CST 2023, time=2023-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1953955, encodeId=6df91953955e5, content=<a href='/topic/show?id=88ece544685' target=_blank style='color:#2F92EE;'>#穿戴设备#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75446, encryptionId=88ece544685, topicName=穿戴设备)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7dc7399, createdName=apoenzyme, createdTime=Wed Jun 14 23:50:46 CST 2023, time=2023-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1700699, encodeId=42db1e006992a, content=<a href='/topic/show?id=82bc38512a4' target=_blank style='color:#2F92EE;'>#可穿戴设备#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38512, encryptionId=82bc38512a4, topicName=可穿戴设备)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db8830213477, createdName=shalley76, createdTime=Fri Mar 31 01:50:46 CST 2023, time=2023-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1361352, encodeId=90521361352cb, content=<a href='/topic/show?id=15ac10083129' target=_blank style='color:#2F92EE;'>#风湿性疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100831, encryptionId=15ac10083129, topicName=风湿性疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Tue Aug 30 15:50:46 CST 2022, time=2022-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1576444, encodeId=135515e644459, content=<a href='/topic/show?id=e02ee6901a2' target=_blank style='color:#2F92EE;'>#系统回顾#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76901, encryptionId=e02ee6901a2, topicName=系统回顾)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=27e316318097, createdName=ms5822920152752585, createdTime=Tue Aug 30 15:50:46 CST 2022, time=2022-08-30, status=1, ipAttribution=)]

相关资讯

A&R:抗磷脂抗体通过Toll样受体4、活性氧和p38 MAPK信号传导增加子宫内膜基质细胞蜕膜、衰老和炎症

抗磷脂抗体增加了人类子宫内膜基质细胞蜕膜、衰老和炎症,为抗磷脂自身抗体阳性女性妊娠并发症的发病机制提供了新的线索,并强调了肝素在预防这一高危人群流产方面的益处。

A&R:核受体4A亚家族信号转导是系统性硬化症中CD1c+树突状细胞失调的关键疾病通路

确定系统性硬化症(SSc)中驱动传统树突状细胞(cDC)改变的关键疾病通路。

JAMA子刊:炎症可能通过激活小胶质细胞和/或星形细胞功能障碍导致大脑结构的变化

由基因决定的IL-6与大脑结构有关,并可能影响发育期神经精神疾病(包括精神分裂症和自闭症)所涉及的区域。

J Clin Periodontol:管理牙龈炎症可有效降低全身炎症水平,提高生活质量

牙菌斑诱发的牙龈炎被定义为主要由牙齿生物膜堆积引起的特定部位的炎症状况。大量研究表明,牙龈炎的存在会影响口腔健康相关的生活质量(OHRQoL),主要是儿童/青少年,但是缺乏关于治疗影响的信息。

CRP、血脂四项只用来看感染和高脂血症?组合使用竟可预示癌症患者结局!

BMC Cancer:癌症患者全身炎症和胰岛素抵抗的预后重要性:前瞻性多中心研究.

J Leukoc Biol:警惕,牙周炎可能会影响全身炎症

炎症是身体对感染或损伤的反应,旨在促进组织和整体的平衡,是常见非传染性疾病的一个关键驱动因素。